Search Results
Your search for ,NOt matches 22378 pages
Showing 4651 - 4700Phase II Trial Reports High Response Rates With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, almost two-thirds of patients with stage II to IV cutaneous squamous cell carcinoma had tumors nearly or completely eradicated by neoadjuvant treatment with cemiplimab-rwlc, an agent targeting PD-1. The results were presented at the European ...
Analysis of Radiotherapy and Breast Cancer Recurrence in the RxPONDER Trial
Do patients with breast cancer and a low 21-gene recurrence score need regional node irradiation to reduce their risk of locoregional recurrence? An analysis of RxPONDER trial data suggests only a randomized clinical trial devoted to this question can provide a decisive answer. An analysis of data...
2022 Annual Report to the Nation on the Status of Cancer Released
Overall cancer death rates continued to decline among men, women, children, adolescents, and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer...
Small Study Examines Repeated Convection-Enhanced Delivery of Topotecan for Recurrent Glioblastoma
In a single-center, small phase Ib trial reported in The Lancet Oncology, Spinazzi et al found that repeated and prolonged convection-enhanced delivery of topotecan prior to surgery was feasible in patients with recurrent glioblastoma and resulted in significant reduction in proliferating tumor...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphomas. Results were presented by Pinnix et al at the 2022 American Society...
Sexual Side Effects of Cancer Treatment Often Unaddressed With Female Patients
A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. Among patients receiving brachytherapy for prostate or cervical cancer at a high-volume cancer...
Medical Physicist Consults May Help Reduce Patient Anxiety and Increase Satisfaction With Radiation Care
Meeting with a medical physicist who can explain how radiation therapy is planned and delivered may reduce patient anxiety and increase patient satisfaction throughout the treatment process, according to a new study published by Burmeister et al in the International Journal of Radiation Oncology •...
FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma
On October 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four...
A Urologic Surgeon Shares His Insights on Robotic Radical Prostatectomy
In 2000, the da Vinci Surgical System broke new ground by becoming the first robotic surgery system approved by the U.S. Food and Drug Administration for general laparoscopic surgery. In its early years, robot-assisted radical prostatectomy was characterized by some in the surgical community as an...
Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy
In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...
Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men
It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...
Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer: Use of Elacestrant in the Phase III EMERALD Trial
Endocrine therapy is the foundation of first-line therapy in most patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Many of these patients respond to endocrine therapy but eventually become resistant to it through both intrinsic and acquired resistance mechanisms....
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
September 12, 2022 “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored the courage and commitment it would take to accomplish this then-audacious goal: ‘We choose to go to the moon in this decade ...
SIO-ASCO Guideline Proposes Evidence-Based Approaches to Pain Management Incorporating Integrative Medicine Interventions
The Society for Integrative Oncology (SIO) and ASCO have released a guideline that appraises the evidence to support incorporating integrative medicine approaches into managing pain in adults with cancer.1 The guideline builds upon existing ASCO guidelines on pain management, the growing body of...
For William L. Dahut, MD, a Career of Service in Oncology
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with William L. Dahut, MD, who is currently serving as Chief Scientific Officer for the American Cancer Society (ACS). In this role, Dr. Dahut manages all pieces of the organization’s discovery work,...
Richter Transformation Remains Challenging, but Better Treatments Are on the Horizon
Richter transformation, usually a diffuse large B-cell lymphoma developing in a person with CLL, remains a challenging entity, but novel regimens look promising, as described at the 2022 Pan Pacific Lymphoma Conference by Matthew S. Davids, MD, MMSc, Associate Professor of Medicine at Harvard...
Incarceration May Be Associated With Higher Cancer Mortality, Yale Study Shows
New research from Yale Cancer Center reveals a higher risk of cancer mortality in incarcerated adults, as well as among those diagnosed with cancer in the first year after release from prison. The findings were published in the journal PLoS One.1 “Cancer is the leading cause of death among people...
Expert Point of View: Bernard Escudier, MD and Brian I. Rini, MD
To put the CheckMate 914, IMmotion010, and PROSPER trials into context, The ASCO Post spoke with Bernard Escudier, MD, former Chair of the Genitourinary Group of the Institut Gustave Roussy, Villejuif, France. In general, Dr. Escudier believes that studies to date are not robust enough to justify...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
A Call for Creativity: The Shades of Gray in Delivery of Goal-Concordant Care
I continue to be struck by the creativity of medical oncologists. The reimagining of dosing, duration, or regimen composition to respond to patient symptoms or preferences is like a master chef in the kitchen. Although standardization has, with good reason, become the paragon, delivering...
Why Are Young Adult Women Developing Later-Stage, More Aggressive Breast Cancer Than Older Women?
It has been well documented that breast cancer is the most common malignancy in adolescent and young adult (AYA) women aged 15 to 39 years, accounting for 30% of cancers among this population.1 In addition, 5.6% of all invasive breast cancers occur in AYA women.1 A presentation by Rebecca H....
IPSOS Trial: Platinum-Ineligible Patients With NSCLC May Gain Survival Benefit From Atezolizumab Therapy
In platinum-ineligible patients with advanced non–small cell lung cancer (NSCLC), first-line treatment with the PD-L1 checkpoint inhibitor atezolizumab improved overall survival by an absolute value of about 1 month but almost doubled the rate of 2-year overall survival compared with chemotherapy...
Prophylactic Radiation for Asymptomatic Bone Metastases May Reduce Pain and Extend Survival
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial were...
PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer
A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk...
Small First-in-Human Trial Investigates FLASH Proton Radiotherapy for Patients With Bone Metastases
FLASH radiation treatment—which delivers therapeutic doses of radiation in a fraction of a second—may be a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests. The technology, previously tested in animals, was shown to be as...
Adding SBRT to Sorafenib May Improve Survival and Time to Disease Progression in Patients With Advanced HCC
Adding stereotactic body radiation therapy (SBRT) to systemic therapy with sorafenib for patients with advanced hepatocellular carcinoma (HCC) may extend overall survival and delay tumor progression without compromising patients’ quality of life, findings from the randomized phase III NRG...
Can Patients With Cancer Treated With Immunotherapy Safely Receive mRNA COVID-19 Vaccines?
New research confirmed the safety of mRNA COVID-19 vaccines in individuals with cancer who are undergoing immunotherapy, according to a novel study published by Widman et al in JNCCN–Journal of the National Comprehensive Cancer Network. The researchers analyzed the frequency of immune-related...
Exercise May Improve Cardiorespiratory Fitness During and After Chemotherapy
During chemotherapy, physical exercise intervention may be safe, improve long-term cardiorespiratory fitness, and alleviate some of the adverse effects of cancer treatment, according to a novel study published by van der Schoot et al in JACC: CardioOncology. The findings suggested that if exercise...
Incidence of Cutaneous Adverse Events With Adjuvant PI3K Inhibitor Therapy
In a systematic review and meta-analysis reported in JAMA Oncology, Jfri et al identified risk for cutaneous adverse events among patients with cancer receiving adjuvant phosphoinositide 3-kinase (PI3K) inhibitor therapy. Study Details The analysis included 15 phase II or III randomized controlled...
Effect of Goals-of-Care Program for Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic
As reported in the Journal of Clinical Oncology by David Hui, MD, MSc, and colleagues, an interdisciplinary goals-of-care program instituted at The University of Texas MD Anderson Cancer Center in response to anticipated COVID-19–related increases in need for intensive care unit (ICU) use resulted ...
Hair-Straightening Chemicals May Be Associated With Higher Uterine Cancer Risk
Individuals who reported using chemical hair-straightening products may be at greater risk for uterine cancer compared to those who did not report using these products, according to a new study published by Chang et al in the Journal of the National Cancer Institute (JNCI). The researchers found no ...
ACS CAN Survey: Female Patients With Cancer Report Less Satisfaction, More Challenges With Cancer Care
Female patients with cancer were less satisfied with the quality of their cancer care than male patients with cancer, according to the results of a survey conducted by the Survivor Views program of the American Cancer Society Cancer Action Network (ACS CAN). In addition, female patients were more...
Use of Remote Interventions Increased Adherence to Cancer Screenings Among Women in Rural Areas
Studies show that rural populations experience greater cancer disparities across the cancer control continuum—from prevention and incidence to survivorship and mortality—compared with their urban counterparts. Those living in rural parts of the United States also tend to have lower cancer screening ...
Maternal Deaths From Cancer Worldwide Have Led to Approximately 1 Million New Maternal Orphans
In 2020, 4.4 million women died from cancer worldwide, leaving behind an estimated 1.04 million maternal orphans (defined as children aged 18 years and younger who have lost their mother), according to the results from a study by Guida et al presented during a press conference at the Union for...
Responses to Irinotecan, Temozolomide, Dinutuximab, and GM-CSF Regimen in Patients With Relapsed High-Risk Neuroblastoma
In a U.S. retrospective study reported in the Journal of Clinical Oncology, Lerman et al found that half of patients with relapsed high-risk neuroblastoma had an objective response to a regimen comprising irinotecan, temozolomide, dinutuximab, and granulocyte-macrophage colony-stimulating factor...
No Benefit for Adjuvant Palbociclib in Stage IIA Breast Cancer: Analysis From the PALLAS Trial
In a preplanned analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with stage IIA breast cancer. Palbociclib offered no additional benefit in terms of invasive disease–free survival (the...
Study Examines Efficacy, Cost of FIT vs Multitarget Stool DNA Testing for Colorectal Cancer Screening
Commercially available noninvasive screening tests for colorectal cancer—the fecal immunochemical test (FIT) and the Cologuard multitarget stool DNA test—are equally effective for screening patients with early-stage colorectal cancer. However, FIT costs about one-fifth of the multitarget stool DNA...
Timely Surveillance With Chest Imaging May Benefit Patients With Metastatic Colorectal Cancer
Patients with colorectal cancer who have certain clinical characteristics may benefit from more frequent chest imaging to help identify and target cancer that has metastasized to the lungs, according to a new study presented at the 2022 Scientific Forum of the American College of Surgeons Clinical...
Single-Dose Carboplatin Plus Involved-Node Radiotherapy in Stage IIA/IIB Seminoma
In a Swiss/German phase II trial (SAKK 01/10) reported in The Lancet Oncology, Papachristofilou et al found that a single dose of carboplatin followed by involved-node radiotherapy narrowly missed the target 3-year progression-free survival rate in patients with stage IIA or IIB seminoma. As...
Study Identifies How Cancer-Causing Gene Might Regulate Genetic Variation in Prostate Cancer
Researchers at the Barts Cancer Institute at the Queen Mary University of London, the Italian Institute for Genomic Medicine, and the University of Milan may have identified a novel role for a cancer-causing gene in controlling an important genetic process that underpins genetic variation in...
Researchers Find Possible Link Between Immune Cells’ Closest Neighbors and Survival Time in Patients With Pancreatic Cancer
Researchers have discovered that the organization of different types of immune cells within pancreatic tumors may be associated with how well patients with pancreatic cancer respond to treatment, as well as how long they survive. This information could eventually lead to new ways of treating...
David Cescon, MD, PhD, Comments on the MONALEESA Analyses
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
MONALEESA Analyses Show Widespread Benefit for Ribociclib in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Further analyses of the MONALEESA metastatic breast cancer trials have shown that the benefit of ribociclib plus endocrine therapy in the first-line setting extends to most intrinsic molecular subtypes and is consistent across multiple subgroups. The studies were presented at the 2021 San Antonio...
Expert Point of View: Mafalda Oliveira, MD, PhD
Invited discussant of the MONALEESA-3 trial, Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, commented: “I totally agree with the authors when they say these results are ‘impressive.’” Among all the phase III trials evaluating...
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor and Chair of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, shared his thoughts on TROPiCS-02 with The ASCO Post. He said the study is important because it addresses the needs of “a population with limited options, whose...
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
Breast Cancer 2021–2022 Almanac
The past year has seen an unprecedented number of practice-changing advances across all three major breast cancer subtypes. For patients with early-stage triple-negative breast cancer, neoadjuvant chemotherapy plus pembrolizumab firmly entered the standard of care based on improvements in...
